Reduction in lipoprotein-associated apoC-III levels following volanesorsen therapy: phase 2 randomized trial results
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Reduction in lipoprotein-associated apoC-III levels following volanesorsen therapy: phase 2 randomized trial results
Authors
Keywords
-
Journal
JOURNAL OF LIPID RESEARCH
Volume 57, Issue 4, Pages 706-713
Publisher
American Society for Biochemistry & Molecular Biology (ASBMB)
Online
2016-02-05
DOI
10.1194/jlr.m066399
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Plasma Apolipoprotein C-III Levels, Triglycerides, and Coronary Artery Calcification in Type 2 DiabeticsSignificance
- (2015) Arman Qamar et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Autotaxin Derived From Lipoprotein(a) and Valve Interstitial Cells Promotes Inflammation and Mineralization of the Aortic ValveCLINICAL PERSPECTIVE
- (2015) Rihab Bouchareb et al. CIRCULATION
- The crucial roles of apolipoproteins E and C-III in apoB lipoprotein metabolism in normolipidemia and hypertriglyceridemia
- (2015) Frank M. Sacks CURRENT OPINION IN LIPIDOLOGY
- The risk of cardiovascular events with increased apolipoprotein CIII: A systematic review and meta-analysis
- (2015) Moritz C. Wyler von Ballmoos et al. Journal of Clinical Lipidology
- Mechanistic insights into Lp(a)-induced IL-8 expression: a role for oxidized phospholipid modification of apo(a)
- (2015) Corey A. Scipione et al. JOURNAL OF LIPID RESEARCH
- Oxidized Phospholipids, Lipoprotein(a), and Progression of Calcific Aortic Valve Stenosis
- (2015) Romain Capoulade et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study
- (2015) Sotirios Tsimikas et al. LANCET
- Chylomicronaemia—current diagnosis and future therapies
- (2015) Amanda J. Brahm et al. Nature Reviews Endocrinology
- Antisense Inhibition of Apolipoprotein C-III in Patients with Hypertriglyceridemia
- (2015) Daniel Gaudet et al. NEW ENGLAND JOURNAL OF MEDICINE
- Apolipoprotein C-III: From Pathophysiology to Pharmacology
- (2015) Giuseppe Danilo Norata et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- Discrimination and Net Reclassification of Cardiovascular Risk With Lipoprotein(a)
- (2014) Peter Willeit et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Pro-Inflammatory Interleukin-1 Genotypes Potentiate the Risk of Coronary Artery Disease and Cardiovascular Events Mediated by Oxidized Phospholipids and Lipoprotein(a)
- (2014) Sotirios Tsimikas et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Loss-of-Function Mutations in APOC3 and Risk of Ischemic Vascular Disease
- (2014) Anders Berg Jørgensen et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeting APOC3 in the Familial Chylomicronemia Syndrome
- (2014) Daniel Gaudet et al. NEW ENGLAND JOURNAL OF MEDICINE
- Loss-of-Function Mutations in APOC3, Triglycerides, and Coronary Disease
- (2014) NEW ENGLAND JOURNAL OF MEDICINE
- Apolipoprotein C-III
- (2013) Murray W. Huff et al. CIRCULATION RESEARCH
- Antisense Oligonucleotide Inhibition of Apolipoprotein C-III Reduces Plasma Triglycerides in Rodents, Nonhuman Primates, and Humans
- (2013) Mark J. Graham et al. CIRCULATION RESEARCH
- Omega-3 free fatty acids for the treatment of severe hypertriglyceridemia: The EpanoVa fOr Lowering Very high triglyceridEs (EVOLVE) trial
- (2013) John J.P. Kastelein et al. Journal of Clinical Lipidology
- Lipoprotein(a): resurrected by genetics
- (2013) F. Kronenberg et al. JOURNAL OF INTERNAL MEDICINE
- Elevated Lipoprotein(a) and Risk of Aortic Valve Stenosis in the General Population
- (2013) Pia R. Kamstrup et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Genetic Associations with Valvular Calcification and Aortic Stenosis
- (2013) George Thanassoulis et al. NEW ENGLAND JOURNAL OF MEDICINE
- A novel omega-3 free fatty acid formulation has dramatically improved bioavailability during a low-fat diet compared with omega-3-acid ethyl esters: The ECLIPSE (Epanova® compared to Lovaza® in a pharmacokinetic single-dose evaluation) study
- (2012) Michael H. Davidson et al. Journal of Clinical Lipidology
- Oxidation-Specific Biomarkers, Prospective 15-Year Cardiovascular and Stroke Outcomes, and Net Reclassification of Cardiovascular Events
- (2012) Sotirios Tsimikas et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Apolipoprotein C‐III as a Potential Modulator of the Association Between HDL‐Cholesterol and Incident Coronary Heart Disease
- (2012) Majken K. Jensen et al. Journal of the American Heart Association
- Low-Density Lipoproteins Containing Apolipoprotein C-III and the Risk of Coronary Heart Disease
- (2011) Carlos O. Mendivil et al. CIRCULATION
- Effects of prescription omega-3-acid ethyl esters, coadministered with atorvastatin, on circulating levels of lipoprotein particles, apolipoprotein CIII, and lipoprotein-associated phospholipase A2 mass in men and women with mixed dyslipidemia
- (2011) Kevin C. Maki et al. Journal of Clinical Lipidology
- Atorvastatin and Fenofibrate Have Comparable Effects on VLDL-Apolipoprotein C-III Kinetics in Men With the Metabolic Syndrome
- (2008) Dick C. Chan et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Tesaglitazar, a dual peroxisome proliferator-activated receptor α/γ agonist, improves apolipoprotein levels in non-diabetic subjects with insulin resistance
- (2007) Herbert Schuster et al. ATHEROSCLEROSIS
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More